Drug Targeting of Oncogenic Pathways in Melanoma

Hematology/Oncology Clinics of North America

Volumn 23, Issue 3, 2009, Pages 599-618

  Fecher, Leslie A ^a   Amaravadi, Ravi K ^a   Schuchter, Lynn M ^a   Flaherty, Keith T ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis; Apoptosis; BRAF; Cell cycle; Drug; KIT; MAPK; Melanoma; Microphthalmia associated transcription factor; Molecular; PI3K

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ABT 263; AG 024322; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BEZ 235; BGT 226; CHIR 265; CISPLATIN; CYCLIN DEPENDENT KINASE; DACARBAZINE; DASATINIB; EVEROLIMUS; FLAVOPIRIDOL; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OBLIMERSEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLX 4032; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN; SCH 727965; SF 1126; SORAFENIB; STEM CELL FACTOR; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147; XL 281; XL 765; ZK 304709;

ADD ON THERAPY; ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL CYCLE; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPIGENETICS; FATIGUE; HAND FOOT SYNDROME; HUMAN; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; VOMITING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASES; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; NEOPLASM PROTEINS; ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 65649118222     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.03.004     Document Type: Review

References (141)

1. van 't Veer L.J., Burgering B.M., Versteeg R., et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 9 7 (1989) 3114-3116
2. Edlundh-Rose E., Egyházi S., Omholt K., et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16 6 (2006) 471-478
3. McGrath J.P., Capon D.J., Goeddel D.V., et al. Comparative biochemical properties of normal and activated human ras p21 protein. Nature 310 (1984) 644-649
4. Sweet R.W., Yokoyama S., Kamata T., et al. The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature 311 (1984) 273-275
5. Schafer W.R., Kim R., Sterne R., et al. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245 (1989) 379-385
6. Schafer W.R., Trueblood C.E., Yang C.C., et al. Enzymatic coupling of cholesterol intermediates to a mating pheromone precursor and to the ras protein. Science 249 (1990) 1133-1139
7. Kohl N.E., Omer C.A., Conner M.W., et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1 (1995) 792-797
8. Nagasu T., Yoshimatsu K., Rowell C., et al. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55 (1995) 5310-5314
9. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3 (2003) 11-22
10. Gajewski TF, Niedzwiecki D, Johnson J, et al. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. vol. 24, No. 18S (June 20 Supplement), 2006:8014.
11. Dent P., Reardon D.B., Morrison D.K., et al. Regulation of Raf-1 and Raf-1 mutants by Ras-dependent and Ras-independent mechanisms in vitro. Mol Cell Biol 15 8 (1995) 4125-4135
12. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 417 6892 (2002) 949-954
13. Tsao H., Goel V., Wu H., et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122 2 (2004) 337-341
14. Wan P.T., Garnett M.J., Roe S.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 6 (2004) 855-867
15. Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4 12 (2004) 937-947
16. Rinehart J., Adjei A.A., Lorusso P.M., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22 22 (2004) 4456-4462
17. Lorusso P.M., Adjei A.A., Varterasian M., et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23 23 (2005) 5281-5293
18. Dummer R., Robert C., Chapman P.B., et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. J Clin Oncol 26 20 suppl (2008) 9033 [abstract]
19. Lorusso P., Krishnamurthi S., Rinehart J.R., et al. A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. (June 1 Supplement). 2005. ASCO Annual Meeting Proceedings Part I. J Clin Oncol vol. 23 No. 16S (2005) 3011
20. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 19 (2004) 7099-7109
21. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95 5 (2006) 581-586
22. Flaherty K.T., Redlinger M., Schuchter L.M., et al. Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma. (June 1 Supplement). 2005. ASCO Annual Meeting Proceedings Part I. J Clin Oncol vol. 23 No. 16S (2005) 3037
23. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 1 (2006) 25-35
24. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
25. Belyanskaya L.L., Hopkins-Donaldson S., Kurtz S., et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 117 (2005) 755-763
26. Ohta T., Ohmichi M., Hayasaka T., et al. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 147 (2006) 1761-1769
27. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18 (2004) 1926-1945
28. Burgering B.M., and Kops G.J. Cell cycle and death control: long live forkheads. Trends Biochem Sci 27 (2002) 352-360
29. Diehl J.A., Cheng M., Roussel M.F., et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12 (1998) 3499-3511
30. Viglietto G., Motti M.L., Bruni P., et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8 (2002) 1136-1144
31. Cardone M.H., Roy N., Stennicke H.R., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
32. Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
33. Mayo L.D., and Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98 (2001) 11598-11603
34. Wu H., Goel V., and Haluska F.G. PTEN signaling pathways in melanoma. Oncogene 22 (2003) 3113-3122
35. Stahl J.M., Sharma A., Cheung M., et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64 (2004) 7002-7010
36. Curtin J.A., Stark M.S., Pinkel D., et al. PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol 126 (2006) 1660-1663
37. Omholt K., Krockel D., Ringborg U., et al. Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res 16 (2006) 197-200
38. Dhawan P., Singh A.B., Ellis D.L., et al. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 62 (2002) 7335-7342
39. Govindarajan B., Sligh J.E., Vincent B.J., et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 117 (2007) 719-729
40. Karbowniczek M., Spittle C.S., Morrison T., et al. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 128 (2008) 980-987
41. Mirmohammadsadegh A., Marini A., Nambiar S., et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 66 (2006) 6546-6552
42. Zhou X.P., Gimm O., Hampel H., et al. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157 (2000) 1123-1128
43. Smalley K.S., Haass N.K., Brafford P.A., et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5 (2006) 1136-1144
44. Curtin J., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 353 (2005) 2135-2147
45. Dankort D, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009 [Epub ahead of print].
46. Yap T.A., Garrett M.D., Walton M.I., et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8 (2008) 393-412
47. Ihle N.T., Williams R., Chow S., et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 3 (2004) 763-772
48. Ihle N.T., Lemos Jr. R., Wipf P., et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69 (2009) 143-150
49. Margolin K., Longmate J., Baratta T., et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104 (2005) 1045-1048
50. Rao R.D., Allred J.B., Windschitl H.E., et al. N0377: results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma. J Clin Oncol 25 (2007) 8530 [abstract]
51. Meier F., Busch S., Lasithiotakis K., et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 156 (2007) 1204-1213
52. Lasithiotakis K.G., Sinnberg T.W., Schittek B., et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 128 (2008) 2013-2023
53. Ernst D.S., Eisenhauer E., Wainman N., et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23 (2005) 569-575
54. Sinnberg T., Lasithiotakis K., Niessner H., et al. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol (2008) [Epub ahead of print]
55. Thallinger C., Poeppl W., Pratscher B., et al. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology 79 (2007) 207-213
56. Thallinger C., Werzowa J., Poeppl W., et al. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. J Invest Dermatol 127 (2007) 2411-2417
57. Thallinger C., Skorjanec S., Soleiman A., et al. Orally administered rapamycin, dacarbazine or both for treatment of human melanoma evaluated in severe combined immunodeficiency mice. Pharmacology 82 (2008) 233-238
58. Curtin J.A., Busam K., Pinkel D., et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24 (2006) 4340-4346
59. Grichnik J.M. Kit and melanocyte migration. J Invest Dermatol 126 (2006) 945-947
60. Hemesath T.J., Price E.R., Takemoto C., et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391 (1998) 298-301
61. Janku F., Novotny J., Julis I., et al. KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res 15 (2005) 251-256
62. Willmore-Payne C., Holden J.A., Hirschowitz S., et al. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 37 (2006) 520-527
63. Willmore-Payne C., Holden J.A., Tripp S., et al. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 36 (2005) 486-493
64. Antonescu C.R., Busam K.J., Francone T.D., et al. L576P kit mutation in anal melanomas correlates with kit protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121 2 (2007) 257-264
65. Beadling C., Jacobson-Dunlop E., Hodi F.S., et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14 (2008) 6821-6828
66. Rivera R.S., Nagatsuka H., Gunduz M., et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 452 (2008) 27-32
67. Satzger I., Schaefer T., Kuettler U., et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 99 (2008) 2065-2069
68. Lasota J., and Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 53 (2008) 245-266
69. Sleijfer S., Wiemer E., Seynaeve C., et al. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist 12 (2007) 719-726
70. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 (2000) 139-145
71. Kim K.B., Eton O., Davis D.W., et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99 (2008) 734-740
72. Ugurel S., Hildenbrand R., Zimpfer A., et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92 (2005) 1398-1405
73. Wyman K., Atkins M.B., Prieto V., et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106 (2006) 2005-2011
74. Fecher L.A., Nathanson K., Flaherty K.T., et al. Phase I/II of imatinib and temozolomide in advanced unresectable melanoma. J Clin Oncol 26 (2008) 9059 [abstract]
75. Hodi F.S., Friedlander P., Corless C.L., et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26 (2008) 2046-2051
76. Chirieac L.R., Trent J.C., Steinert D.M., et al. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer 107 (2006) 2237-2244
77. Medeiros F., Corless C.L., Duensing A., et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28 (2004) 889-894
78. Lutzky J., Bauer J., and Bastian B.C. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21 (2008) 492-493
79. Schittenhelm M.M., Shiraga S., Schroeder A., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66 (2006) 473-481
80. Schwartz G.K., and Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23 (2005) 9408-9421
81. Berthet C., Aleem E., Coppola V., et al. Cdk2 knockout mice are viable. Curr Biol 13 (2003) 1775-1785
82. Hussussian C.J., Struewing J.P., Goldstein A.M., et al. Germline p16 mutations in familial melanoma. Nat Genet 8 1 (1994) 15-21
83. Sauter E.R., Yeo U.C., von Stemm A., et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62 (2002) 3200-3206
84. Li W., Sanki A., Karim R.Z., et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 38 4 (2006 Aug) 287-301
85. Zuo L., Weger J., Yang Q., et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12 1 (1996) 97-99
86. Georgieva J., Sinha P., and Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol 54 (2001) 229-235
87. Du J., Widlund H.R., Horstmann M.A., et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6 (2004) 565-576
88. Bhatt K.V., Hu R., Spofford L.S., et al. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene 26 (2007) 1056-1066
89. Smalley K.S., Lioni M., Dalla Palma M., et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 7 (2008) 2876-2883
90. Smalley K.S., Contractor R., Nguyen T.K., et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res 68 (2008) 5743-5752
91. Fry D.W., Harvey P.J., Keller P.R., et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3 (2004) 1427-1438
92. Toogood P.L., Harvey P.J., Repine J.T., et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 48 (2005) 2388-2406
93. O'Dwyer P.J., LoRusso P., DeMichele A., et al. A phase I dose escalation trial of daily oral CDK 4/6 inhibitor PD-0332991. J Clin Oncol 25 (2007) 3550 [abstract]
94. Wang Y, et al. SCH 727965, a novel small cyclin-dependent kinase inhibitor, has potent anti-tumor activity in a wide-spectrum of human tumor xenograft models. AACR 2008 [abstract 1594].
95. Parry D, et al. In vitro and in vivo characterization of SCH727965 a novel potent cyclin dependent kinase inhibitor. AACR 2007 [abstract 4371].
96. Shapiro GI, et al. A phase I dose escalation study of the safety, pharmacokinetics and pharmacodynamics of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 32 weeks in subjects with advanced malignancies. ASCO 2008 [abstract 3532].
97. Heath E.I., Bible K., Martell R.E., et al. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 26 (2008) 59-65
98. Brown A.P., Courtney C.L., Criswell K.A., et al. Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion. Cancer Chemother Pharmacol 62 (2008) 1091-1101
99. Ahmed S., Molife R., Shaw H., et al. Phase I dose-escalation study of ZK 304709, an oral multitarget tumor growth inhibitor (MTGI), administered for 14 days of a 28-day cycle. J Clin Oncol 24 (2006) 2076 [abstract]
100. Graham J., Wagner K., Plummer R., et al. Phase I dose-escalation study of novel oral multitarget tumor growth inhibitor (MTGI) ZK 304709 administered daily for 7 days of a 21-day cycle to patients with advanced solid tumors. J Clin Oncol 24 (2006) 2073 [abstract]
101. Burdette-Radoux S., Tozer R.G., Lohmann R.C., et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 22 (2004) 315-322
102. Garraway L.A., Widlund H.R., Rubin M.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436 (2005) 117-122
103. Levy C., Khaled M., and Fisher D.E. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12 (2006) 406-414
104. Hemesath T.J., Steingrimsson E., McGill G., et al. Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 8 (1994) 2770-2780
105. Carreira S., Goodall J., Aksan I., et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433 (2005) 764-769
106. McGill G.G., Horstmann M., Widlund H.R., et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109 (2002) 707-718
107. Loercher A.E., Tank E.M., Delston R.B., et al. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 168 (2005) 35-40
108. Yokoyama S., Feige E., Poling L.L., et al. Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 21 (2008) 457-463
109. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26 (2007) 5541-5552
110. Olsen E.A., Kim Y.H., Kuzel T.M., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (2007) 3109-3115
111. Hauschild A., Trefzer U., Garbe C., et al. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res 18 (2008) 274-278
112. Iervolino A., Trisciuoglio D., Ribatti D., et al. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 16 (2002) 1453-1455
113. Trisciuoglio D., Desideri M., Ciuffreda L., et al. Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol 205 (2005) 414-421
114. Sheridan C., Brumatti G., and Martin S.J. Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. J Biol Chem 283 (2008) 22128-22135
115. Smalley K.S., Xiao M., Villanueva J., et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28 (2009) 85-94
116. Zeitlin B.D., Zeitlin I.J., and Nor J.E. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol 26 (2008) 4180-4188
117. Oblimersen: augmerosen, BCL-2 antisense oligonucleotide-Genta, G 3139, GC 3139, oblimersen sodium. Drugs R D 8 (2007) 321-334
118. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24 (2006) 4738-4745
119. Chana J.S., Wilson G.D., Cree I.A., et al. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol 83 (1999) 110-114
120. Saenz-Santamaria M.C., Reed J.A., McNutt N.S., et al. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. J Cutan Pathol 21 (1994) 393-397
121. Miller L.A., Goldstein N.B., Johannes W.U., et al. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol 129 4 (2009 Apr) 964-971
122. Cragg M.S., Jansen E.S., Cook M., et al. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 118 (2008) 3651-3659
123. Vogler M., Butterworth M., Majid A., et al. Concurrent upregulation of BCL-XL and BCL2A1 induces ∼1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood (2008) 10.1182/blood-2008-08-173310
124. Wong R.P., Khosravi S., Martinka M., et al. Myeloid leukemia-1 expression in benign and malignant melanocytic lesions. Oncol Rep 19 (2008) 933-937
125. Zhuang L., Lee C.S., Scolyer R.A., et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 20 (2007) 416-426
126. Konopleva M., Contractor R., Tsao T., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10 (2006) 375-388
127. Wolter K.G., Verhaegen M., Fernandez Y., et al. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 14 (2007) 1605-1616
128. Lum J.J., Bauer D.E., Kong M., et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120 (2005) 237-248
129. Amaravadi R.K., and Thompson C.B. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 13 (2007) 7271-7279
130. Amaravadi R.K., Yu D., Lum J.J., et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117 (2007) 326-336
131. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 2 (2007) 125-134
132. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 1 (2006) 16-24
133. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 5 (2003) 427-434
134. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
135. Kindler H.L., Niedzwiecki D., Hollis D., et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 25 1 (2007) 4508
136. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 26 (2007) 2666-2676
137. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 24 (2006) 2542-2550
138. Varker K.A., Biber J.E., Kefauver C., et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14 8 (2007) 2367-2376
139. McDermott D.F., Sosman J.A., Hodi F.S., et al. Randomized phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma. J Clin Oncol 34 (2007) 275
140. Perez D.G., Suman V.J., Fitch T.R., et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 115 1 (2009) 119-127
141. Korn E.L., Liu P.Y., Lee S.J., et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26 4 (2008) 527-534